SouthState Corp’s Esperion Therapeutics ESPR Stock Holding History

SouthState Corp’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-314	Closed	-$518	–	685
2024 Q3	$518	Hold	314	–	–	﹤0.01%	594
2024 Q2	$697	Hold	314	–	–	﹤0.01%	620
2024 Q1	$842	Hold	314	–	–	﹤0.01%	654
2023 Q4	$939	Hold	314	–	–	﹤0.01%	569
2023 Q3	$308	Hold	314	–	–	﹤0.01%	617
2023 Q2	$436	Hold	314	–	–	﹤0.01%	581
2023 Q1	$499	Hold	314	–	–	﹤0.01%	631
2022 Q4	$1.96K	Hold	314	–	–	﹤0.01%	652
2022 Q3	$2K	Hold	314	–	–	﹤0.01%	639
2022 Q2	$2K	Hold	314	–	–	﹤0.01%	667
2022 Q1	$1K	Hold	314	–	–	﹤0.01%	689
2021 Q4	$2K	Hold	314	–	–	﹤0.01%	681
2021 Q3	$4K	Buy	+314	New	+$4.57K	﹤0.01%	534

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SouthState Corp's ESPR Position: Q4 2024 in Review

SouthState Corp sold out of Esperion Therapeutics (ESPR) in Q4 2024, closing a stake of 314 shares — an estimated $518 sold.

SouthState Corp first reported a position in ESPR in Q3 2021 and held it in 13 quarters. The position peaked at $4K in Q3 2021. 190 funds tracked by Wall St. Rank hold ESPR as of Q4 2024.

SouthState Corp reported no remaining Esperion Therapeutics position as of Q4 2024 after selling out during the quarter.
SouthState Corp sold 314 Esperion Therapeutics shares in Q4 2024, an estimated $518.
SouthState Corp first reported a position in Esperion Therapeutics in Q3 2021 and held it in 13 quarters.
SouthState Corp's Esperion Therapeutics position peaked at $4K in Q3 2021.
190 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2024.

Based on SouthState Corp's 13F filing for Q4 2024, filed 10 Feb 2025.